GSDMC-increased efficacy of PARPi was observed in BRCA-deficient (Figure 1E and Figure 2F) and BRCA-proficient (Figure 1G and Figure 2C) cells, indicating that BRCA deficiency is not absolutely required for, but seems to strengthen, the effects for GSDMC-sensitizing tumor cells to PARPi. The gene discussed is GSDMC; the disease is neoplasm.